Next Article in Journal
Cryptococcus: Shedding New Light on an Inveterate Yeast
Next Article in Special Issue
The Immunologic Response to Trichophyton Rubrum in Lower Extremity Fungal Infections
Previous Article in Journal
Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients
Previous Article in Special Issue
Laser Therapy for Onychomycosis: Fact or Fiction?
Open AccessReview

Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success

San Antonio Podiatry Associates, San Antonio, TX 78229, USA
Dow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America LLC, Petaluma, CA 94954, USA
Kaken Pharmaceutical Co. Ltd., Kyoto 607-8042, Japan
Author to whom correspondence should be addressed.
Academic Editor: Theodore Rosen
J. Fungi 2015, 1(2), 107-114;
Received: 1 June 2015 / Revised: 23 June 2015 / Accepted: 24 June 2015 / Published: 3 July 2015
(This article belongs to the Special Issue Cutaneous Fungal Diseases)
To provide an adequate therapeutic effect against onychomycosis, it has been suggested that topical drugs should have two properties: drug permeability through the nail plate and into the nail bed, and retention of their antifungal activity in the disease-affected areas. Only recently has the importance of other delivery routes (such as subungual) been discussed. Efinaconazole has been shown to have a more potent antifungal activity in vitro than the most commonly used onychomycosis treatments. The low keratin affinity of efinaconazole contributes to its effective delivery through the nail plate and retention of its antifungal activity. Its unique low surface tension formulation provides good wetting properties affording drug delivery both through and under the nail. High antifungal drug concentrations have been demonstrated in the nail of onychomycosis patients, and effectiveness of efinaconazole topical solution, 10% confirmed in two large well-controlled multicenter Phase 3 clinical studies in patients with mild-to-moderate disease. View Full-Text
Keywords: onychomycosis; efinaconazole; topical therapy; fungi; toenail onychomycosis; efinaconazole; topical therapy; fungi; toenail
Show Figures

Figure 1

MDPI and ACS Style

Pollak, R.A.; Siu, W.J.J.; Tatsumi, Y.; Pillai, R. Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success. J. Fungi 2015, 1, 107-114.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop